Roivant Sciences Ltd. (ROIV) intrinsic value & 10-year financials
Roivant Sciences Ltd. (ROIV) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue shrank 19.1% a year to $8.3M, with an average return on invested capital of 94.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $33.53
- Market cap
- $23.3B
- Revenue (FY2026)
- $8.3M
- Revenue growth (7-yr CAGR)
- -19.1%
- ROIC (10-yr avg)
- 94.0%
- Free cash flow (FY2026)
- -$758.6M
ROIV 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | $8.3M | -$299.8M | -$0.54 | -$758.6M | -6235.7% | -19.6% |
| FY2025 | $29.1M | -$172.0M | -$0.24 | -$844.0M | -3453.3% | -101.2% |
| FY2024 | $124.8M | $4.3B | $5.23 | -$766.6M | 3399.2% | -6737.8% |
| FY2023 | $61.3M | -$1.0B | -$1.42 | -$856.1M | -1917.9% | 1330.1% |
| FY2022 | $55.3M | -$845.3M | -$1.26 | -$695.2M | -2444.8% | 1737.8% |
| FY2021 | $23.8M | -$809.2M | — | -$557.9M | -4500.5% | 4354.7% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Roivant Sciences Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Roivant Sciences Ltd. has historically struggled to out-earn its cost of capital, averaging just -19.0% ROIC.
Roivant Sciences Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Roivant Sciences Ltd. is modeled at -19.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-133.74 per share.